Overview

A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

Phase II study that will evaluate the activity of gemcitabine as intravesical therapy on the marker lesion in superficial bladder carcinoma at intermediate risk. Primary objective is the evaluation of the pathological complete response after 8 instillation of gemcitabine. 46 patients are requested.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Aventis Pharmaceuticals

Treatments:

Cisplatin
Docetaxel
Gemcitabine